CaPtivate Pharmaceuticals LLC was incorporated in 2011 as a spin-off from BioSante Pharmaceuticals (currently ANI Pharmaceuticals).  It is a preclinical-stage biotechnology company based in greater Philadelphia - Pennsylvania Biotechnology Incubator, Doylestown PA. The company is focused on developing its proprietary CaP nanoparticle vaccine adjuvant and delivery platform (CaPtivantTM) for advancement of novel and improved vaccines against life-treating diseases.


Establishing collaborations and partnerships within industrial, academic, non-profit, and government organizations is the foundation of CaPtivate’s business strategy. We actively seek partners in human and veterinary vaccine R&D who are searching for a safe and effective vaccine adjuvant/delivery system that enables:


    • Broad spectrum of immune responses, including humoral, mucosal, CTL,
    • Mucosal administrations including pulmonary, intranasal, intravaginal,
    • Formulations as particulate suspension or as stable powders.

We make CaP nanoparticles available to interested parties for evaluation in their vaccine programs and through collaborative research agreements or Material Transfer Agreements (MTA). The technology is also available for licensing under exclusive or non-exclusive terms.


To explore partnering and collaboration opportunities with CaPtivate, please send us an email at or call us at (215)298-3032.